Dr Alva is a board-certified psychiatrist, a paid consultant of Otsuka America Pharmaceutical, Inc, and Lundbeck, and Mood Disorders Section Editor for Psychiatric Times.
Panelists discuss the vital but often underutilized role of psychotherapy in schizophrenia treatment, emphasizing the need for accessible, tailored interventions such as cognitive behavioral therapy (CBT) for psychosis to complement medication and address persistent functional and cognitive challenges.
Panelists discuss how prescription digital therapeutics (PDTs) can complement pharmacologic treatments in schizophrenia by addressing persistent negative and cognitive symptoms—such as motivation, social engagement, and executive function—that often go untreated, highlighting the need for a more holistic, patient-centered approach to care.
Gus Alva, MD, discusses the FDA committee vote on brexpiprazole for PTSD, what it means, and what's next.
The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.
Gus Alva, MD, discusses how he will be examining notable challenges in schizophrenia care, including access issues, and exploring the potential role of prescription digital therapeutics in addressing these gaps.
Different medications for different domains: new treatments are changing the way schizophrenia is managed.
Here's what patients should know about Cobenfy for the treatment of schizophrenia.
How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?
In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.
After 40 years, Psychiatric Times is still your go-to resource for all things psychiatry. Just ask our Mood Disorders Section Editor.
While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.
Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.
Our Mood Disorders Section Editor shares his thoughts on this year's biggest clinical trial successes and failures.
What are the most pressing issues facing psychiatry? Gustavo Alva, MD, FAPA, shares his thoughts.
Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.
Here are 10 things to consider when treating a patient with mood disorders.
Check out these top 10 best practices for treating patients with mood disorders.
Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.
The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.
Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.
Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.
Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.
Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.
Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.
Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
